Services for this record from Sandia Technical Library
Title: Raltegravir
Source: Nature Reviews Drug Discovery [1474-1776] Deeks, Steven yr:2008 vol:7 iss:2 pg:117 -118
Full Text Online Nature GO
Available from 2002 volume: 1 issue:1
Request through RightFind document delivery
*User ID (e.g., jroppen):
GO
Users interested in this article also expressed an interest in the following:
1. Cahn, P. "Raltegravir: a new antiretroviral class for salvage therapy." The lancet 369.9569 (2007): 1235-6. Link to SFX for this item
2. Joy, T. "Is raising HDL a futile strategy for atheroprotection?" Nature reviews. Drug discovery 7.2 (2008): 143-155. Link to SFX for this item
3. Liedtke, M. "Long-term efficacy and safety of raltegravir in the management of HIV infection." Infection and Drug Resistance 7 (2014): 73-84. Link to SFX for this item
4. Croxtall, Caroline M D. Drugs 68.1 (2008): 131-138. Link to SFX for this item
5. Isaacs, Robin D D. "Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial." The lancet 369.9569 (2007): 1261-9. Link to SFX for this item
View More...
View Less...
Select All Clear All
Expand list of advanced services More Options